5/2025 Amendment and Execution of Loan Agreements with BioFund
Current Report No: 4/2025 Date: April 15, 2025 Legal Basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council (MAR) – inside information The Management Board of Medicalgorithmics S.A., with its registered office in Warsaw (the “Company”), hereby announces that on April 15, 2025, it entered into a […]
4/2025 Medicalgorithmics Signs Fourth Service Agreement for a Clinical Study with a Canadian Institute, Projecting a Total Revenue of EUR 580K by 2026
Current Report No: 4/2025 Date: Febraury 4, 2025. Legal Basis: Article 17(1) of the MAR Regulation – Confidential Information The Management Board of Medicalgorithmics S.A., headquartered in Warsaw (the “Company”; the “Issuer”), announces the signing of a service agreement (the “Agreement”) with Hamilton Health Sciences Corporation (“HHSC”) through the Population Health Research Institute (“PHRI”; the […]
3/2025 Correction – Schedule of Periodic Reports for 2025
Current Report No: 3/2025 Date: February 2, 2025. Legal Basis: Article 56(1)(2) of the Act on Public Offering – Current and Periodic Information The Management Board of Medicalgorithmics S.A., based in Warsaw (the “Company”), corrects an obvious clerical error in current report No. 1 dated January 22 of this year and clarifies that the standalone […]
2/2025 Medicalgorithmics S.A. Signs Contract with US IDTF with Estimated Revenue Potential of up to PLN 46 Million Over Two Years
Current Report No: 2/2025 Date: January 24, 2025. Legal Basis: Article 17(1) of the MAR Regulation – Confidential Information Medicalgorithmics S.A., headquartered in Warsaw (the “Company”; the “Issuer”), announces that on January 24, 2025, it signed a significant agreement (the “Agreement”) with a U.S.-based diagnostic center (IDTF, the “Partner”). The signing of this Agreement is […]
1/2025 Schedule of Periodic Reports for 2025
Current Report No: 1/2025 Date: January 22, 2025. Legal Basis: Article 56(1)(2) of the Act on Public Offering – Current and Periodic Information The Management Board of Medicalgorithmics S.A., headquartered in Warsaw (the “Company”), hereby announces the schedule for the publication of periodic reports in 2025: 1.Standalone Annual Report and Consolidated Annual Report for 2023 […]
22/2024 Information on the Completion of the CE Certification Process for VCAST Technology by Medicalgorithmics S.A.
Current Report No: 22/2024 Date: 17.10.2024 r. Legal Basis: Article 17(1) of the MAR Regulation – confidential information. The Management Board of Medicalgorithmics S.A., based in Warsaw (“Company”; “Issuer”), informs that the Company has received notification from the notified body TÜV Rheinland Polska Sp. z o.o. regarding the successful completion of the CE certification process […]
21/2024 Change of the publication date of the semi-annual report for the first half of 2024
Current Report No: 21/2024 Date: 20.08.2024 r. Legal Basis: Article 56(1)(2) of the Act on Public Offering – current and periodic information The Management Board of Medicalgorithmics S.A., based in Warsaw (the “Company”), hereby announces a change in the publication date of the semi-annual report for the first half of 2024 (the “Report”). The Report […]
20/2024 Assimilationof Series J Shares of the Company with Shares Traded on the Main Market
Current Report No: 20/2024 Date: 19.09.2024 r. Legal Basis: Article 56_1__2_ of the Act on Public Offering – Current andPeriodic Information The Management Board of Medicalgorithmics S.A., based in Warsaw _the “Company”_, in reference to the Company’s current report No. 19/2024 dated September 13, 2024, hereby announces that it has receivedinformation regarding the issuance […]
19/2024 Admissionand conditional introduction of the Company’s series J shares to tradingon the main market of the WSE. Setting the date of the first listing ofthe Company’s series J shares after their assimilation with sharestraded on the main market.
Current Report No: 19/2024 Date: 13.09.2024 r. Legal Basis: Article 56_1__2_ of the Act on Public Offering – Current andPeriodic Information The Management Board of Medicalgorithmics S.A. with its registered office in Warsaw _the “Issuer”, the “Company”_, hereby announces that on 13 September 2024 it received information on the adoption of Resolution No. 1134/2024 of […]
18/2024 Notification of the receipt by Medicalgorithmics S.A. of USD 0.6 million from the React Group as a price adjustment for the sale of Medi-LynxDate
Current Report No: 18/2024 Date: 20.08.2024 r. Legal Basis: Article 17, Section 1 of the MAR Regulation – Confidential Information The Management of Medicalgorithmics S.A., based in Warsaw the “Company”, announces that in reference to the Company’s current report No. 3/2024, on August 20, 2024, the Company received USD 0.6 million approx. 2.3 million PLN from […]
17/2024 Conversion of Registered Series J Shares to Bearer Shares
Current Report No: 17/2024 Date: 19.08.2024 r. Legal Basis: Article 17, Section 1 of the MAR Regulation – Confidential Information The Management of Medicalgorithmics S.A., based in Warsaw “Company”, informs that on August 19, 2024, a resolution was adopted regarding the conversion of registered ordinary Series J shares into bearer ordinary shares “Resolution”. By virtue of […]
16/2024 Information on Medicalgorithmics S.A.’s Agreement to Establish a LoanLine with BioFund Capital Management LLC
Current Report No: 16/2024 Date: 26.06.2024 r. Legal Basis: Article 17, Section 1 of the MAR Regulation – Confidential Information The Management Board of Medicalgorithmics S.A., based in Warsaw “Company”, announces the signing of an agreement on June 25, 2024, to establish a loan line “Agreement” with the Company’s shareholder, BioFund Capital Management LLC “BioFund”. The […]